Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Researchers Coax Secrets, Possible Drug Targets From Multiple Myeloma Genome

This article was originally published in The Pink Sheet Daily

Executive Summary

The whole genome study suggests new targets for the incurable bone-marrow cancer, but even the nearest at hand could be years away from producing a therapeutic agent.

You may also be interested in...



Plexxikon CEO: Expect Business As Usual, After Whopping $805 Million Daiichi Sankyo Buyout

Bidding by multiple companies and strong data for a late-stage, targeted melanoma drug helped drive Daiichi Sankyo Company Limited's eye-popping $805 million acquisition of privately-held Plexxikon Inc.

Plexxikon, Roche Near Catalyst For BRAF Inhibitor In Melanoma

As its melanoma drug advances in the clinic, Plexxikon obtains rights to co-promote it in the U.S.

Myeloma Foundation Uses Patient Connections To Help Speed Drug Trials

Bolstered by a huge patient database, the Multiple Myeloma Research Consortium is helping to speed trials of new therapies, including some of the most talked about investigational drugs in the disease space, like carfilzomib and pomalidomide.

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel